10X Genomics (TXG) Stock Forecast & Price Target

10x Genomics is supported by a compelling long-term growth profile because its integrated instruments, consumables, and software ecosystem is designed to capture recurring demand as customers expand multiomic and spatial biology workflows. The company’s Chromium, Visium, and Xenium platforms address complex biological analysis at scale, giving it a differentiated position in a market where technology depth and installed-base monetization can support durable revenue growth. In addition, its geographic reach across the United States, Europe, China, Asia-Pacific, and other regions broadens the addressable market and reduces reliance on any single end market.

10x Genomics is facing a negative fundamental setup because market competition, technological obsolescence, regulation, dependence on key customers, and supply chain disruptions all threaten its ability to sustain growth and protect margins. Its recent production results were below estimates and consensus, with gold at 69.3 koz versus 78.8 koz estimated, copper at 13.9 Mlbs versus 15.3 Mlbs estimated, and silver at 520.2 koz versus 549.7 koz estimated, signaling execution risk and weaker-than-expected operating performance. Although 2026 guidance of 420–470 koz AuEq was reiterated, the reliance on planned lower grades and recoveries with improvement only stepping into H2/26 leaves limited near-term visibility and reinforces a cautious outlook.